comparemela.com

Andre Uddin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

THTX stock keeps Buy rating at Research Capital

Following the company’s fourth quarter results, Research Capital analyst Andre Uddin has maintained his “Buy” rating on Theratechnologies.

Andre uddinResearch capitalTheratechnologies stock quoteNet loss

MDNA is undervalued, Research Capital says

Following the company’s third quarter results, Research Capital analyst Andre Uddin has kept his “Speculative Buy” rating on Medicenna Therapeutics

Merck keytrudaAndre uddinResearch capitalSociety for neuroMedicenna therapeuticsMedicenna therapeutics stock quote

Medexus earns price target raise at Research Capital

Following moves by the company to shore up its balance sheet, Research Capital analyst Andre Uddin is feeling a little more bullish about MDP.

Andre uddinMedexus pharmaceuticals stockResearch capitalMedexus pharmaceuticalsMedexus pharmaceuticals stock quote

Sernova (TSX:SVA) stock is cheap, Research Capital says

Following the release of new data on a core offering, Research Capital analyst Andre Uddin remains upbeat about the prospects of Sernova.

United statesCynthia pussinenAndre uddinAmerican thyroid associationResearch capitalSernova stock quoteCell pouchThyroid associationCell pouch system

SVA stock is undervalued, Research Capital says

A management shuffle at Sernova Corp isn’t dampening analyst Andre Uddin’s enthusiasm for the stock..

Brett whalenCynthia pussinenAndre uddinPhilip toleikisIpsen biosciencesIpsen biomeasureSpark therapeutics incSernova corp stockRoche groupTechnology officerSernova corpSernova corp stock quoteChief technologyChief executive officerChief technology officerChief technical officer

vimarsana © 2020. All Rights Reserved.